A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19
出版年份 2020 全文链接
标题
A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19
作者
关键词
-
出版物
Nature Communications
Volume 11, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-10-15
DOI
10.1038/s41467-020-19055-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
- (2020) Manli Wang et al. CELL RESEARCH
- A pneumonia outbreak associated with a new coronavirus of probable bat origin
- (2020) Peng Zhou et al. NATURE
- A Novel Coronavirus from Patients with Pneumonia in China, 2019
- (2020) Na Zhu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
- (2020) Emmie de Wit et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
- (2020) Timothy P. Sheahan et al. Nature Communications
- Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential
- (2020) Jimin Xu et al. ACS Infectious Diseases
- Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
- (2020) Sangeun Jeon et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract
- (2020) Yixuan J. Hou et al. CELL
- An Infectious cDNA Clone of SARS-CoV-2
- (2020) Xuping Xie et al. Cell Host & Microbe
- Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
- (2020) Eli S. Rosenberg et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
- (2020) Calvin J. Gordon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
- (2020) Jianjun Gao et al. BioScience Trends
- Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
- (2020) Philippe Gautret et al. Travel Medicine and Infectious Disease
- Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
- (2020) Ka-Tim Choy et al. ANTIVIRAL RESEARCH
- Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study
- (2020) Abdo A. Elfiky LIFE SCIENCES
- No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection
- (2020) J.M. Molina et al. MEDECINE ET MALADIES INFECTIEUSES
- Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
- (2020) Brandi N. Williamson et al. NATURE
- A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
- (2020) Antonio E. Muruato et al. Nature Communications
- Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
- (2020) Rodrigo Jácome et al. Scientific Reports
- Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice
- (2020) Andrea J. Pruijssers et al. Cell Reports
- Discovery of the Pan-genotypic Hepatitis C Virus NS3/4A Protease Inhibitor Voxilaprevir (GS-9857): A Component of Vosevi ®
- (2019) James G. Taylor et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Discovery of velpatasvir (GS-5816): a potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi® and Epclusa.®
- (2019) John O. Link et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Targeting BTK in CLL: Beyond Ibrutinib
- (2019) David A. Bond et al. Current Hematologic Malignancy Reports
- A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
- (2019) Francisco M Marty et al. CLINICAL INFECTIOUS DISEASES
- In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit
- (2018) Takeshi Noshi et al. ANTIVIRAL RESEARCH
- Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults
- (2017) Joel E. Gallant et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses
- (2017) Dustin Siegel et al. JOURNAL OF MEDICINAL CHEMISTRY
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
- (2017) Timothy P. Sheahan et al. Science Translational Medicine
- Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment
- (2016) Joseph M. Custodio et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Distinct Effects of T-705 (Favipiravir) and Ribavirin on Influenza Virus Replication and Viral RNA Synthesis
- (2016) Evelien Vanderlinden et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Design and structure–activity relationships of novel inhibitors of human rhinovirus 3C protease
- (2016) S.P. Kawatkar et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- An Infectious cDNA Clone of Zika Virus to Study Viral Virulence, Mosquito Transmission, and Antiviral Inhibitors
- (2016) Chao Shan et al. Cell Host & Microbe
- SARS and MERS: recent insights into emerging coronaviruses
- (2016) Emmie de Wit et al. NATURE REVIEWS MICROBIOLOGY
- GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process
- (2015) Michel Perron et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Molecular Basis for the Selective Inhibition of Respiratory Syncytial Virus RNA Polymerase by 2'-Fluoro-4'-Chloromethyl-Cytidine Triphosphate
- (2015) Jerome Deval et al. PLoS Pathogens
- Coronavirus reverse genetic systems: Infectious clones and replicons
- (2014) Fernando Almazán et al. VIRUS RESEARCH
- Preclinical Characterization of the Novel Hepatitis C Virus NS3 Protease Inhibitor GS-9451
- (2013) Huiling Yang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of chloroquine on feline infectious peritonitis virus infection in vitro and in vivo
- (2013) Tomomi Takano et al. ANTIVIRAL RESEARCH
- Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults
- (2013) Peter J. Ruane et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Discovery of GS-9669, a Thumb Site II Non-Nucleoside Inhibitor of NS5B for the Treatment of Genotype 1 Chronic Hepatitis C Infection
- (2013) Scott E. Lazerwith et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of the First C-Nucleoside HCV Polymerase Inhibitor (GS-6620) with Demonstrated Antiviral Response in HCV Infected Patients
- (2013) Aesop Cho et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection
- (2013) John O. Link et al. JOURNAL OF MEDICINAL CHEMISTRY
- Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus
- (2013) T. Scobey et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A 2′-Deoxy-2′-Fluoro-2′-C-Methyl Uridine Cyclopentyl Carbocyclic Analog and Its Phosphoramidate Prodrug as Inhibitors of HCV NS5B Polymerase
- (2012) Jian Liu et al. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
- Mechanistic Characterization of GS-9190 (Tegobuvir), a Novel Nonnucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase
- (2011) I-hung Shih et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Development and characterization of a stable luciferase dengue virus for high-throughput screening
- (2011) Gang Zou et al. ANTIVIRAL RESEARCH
- Discovery of GS-9256: A novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity
- (2011) X. Christopher Sheng et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis
- (2011) Vlad Ratziu et al. HEPATOLOGY
- Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study
- (2011) L. Zhu et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer
- (2010) Lianhong Xu et al. ACS Medicinal Chemistry Letters
- Robust Antiviral Efficacy upon Administration of a Nucleoside Analog to Hepatitis C Virus-Infected Chimpanzees
- (2008) S. S. Carroll et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started